Drug Safety Alert: IPC Flags ADR Linked To Vancomycin

New Delhi: The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of July, has revealed that Vancomycin, a tricyclic glycopeptide antibiotic, is linked with adverse drug reactions (ADRs) named Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.

In connection with the above, the Indian Pharmacopoeia Commission (IPC) has cautioned healthcare professionals to diligently monitor the potential occurrence of adverse drug reactions (ADRs) when administering vancomycin.

This came after a preliminary analysis of adverse drug reactions (ADRs) from the Pharmacovigilance Programme of India (PVPI) database.

Vancomycin is a glycopeptide antibiotic used to treat severe but susceptible bacterial infections such as MRSA (methicillin-resistant Staphylococcus aureus) infections.

The alert noted that vancomycin is indicated for the treatment of serious infections due to Gram-positive cocci, including methicillin-resistant staphylococcal infections, brain abscesses, staphylococcal meningitis, and septicaemia.

Following the preliminary analysis of adverse drug reactions (ADRs) from the PVPI database, it is reported that vancomycin can lead to Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.

The Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome presents clinically as an extensive mucocutaneous rash, accompanied by fever, lymphadenopathy, hepatitis, hematologic abnormalities with eosinophilia, and atypical lymphocytes.

In light of the above, the Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, has advised healthcare professionals, patients, and consumers to closely monitor the possibility of the above ADRs associated with the use of the above-suspected drugs.

Further, the safety alert added, “If such reaction is encountered, please report to the NCC-PVPI, IPC by filling out Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (http://www.ipc.gov.in), through Android Mobile App “ADR PvPI App” and PvP Helpline No. 1800-180-3024 (Toll-Free).”

Related Posts

Nearly Three in Ten Products in Indian Local Markets Perceived as Counterfeit; Pharmaceuticals and FMCG among Worst-Affected Sectors: ASPA–CRISIL Intelligence Report

New Delhi: Nearly 29% of products available in India’s local markets are perceived by consumers to be counterfeit, highlighting the growing challenge of fake goods across critical sectors, including pharmaceuticals…

Culture reports reveal bacteria damaged cornea of five patients from Kuchaman

Jaipur: Culture reports confirmed that five patients shifted to SMS Hospital, Jaipur, after cataract surgery at Kuchaman govt hospital have tested positive for serious postoperative eye infections caused by Enterobacter…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Nearly Three in Ten Products in Indian Local Markets Perceived as Counterfeit; Pharmaceuticals and FMCG among Worst-Affected Sectors: ASPA–CRISIL Intelligence Report

Nearly Three in Ten Products in Indian Local Markets Perceived as Counterfeit; Pharmaceuticals and FMCG among Worst-Affected Sectors: ASPA–CRISIL Intelligence Report

Culture reports reveal bacteria damaged cornea of five patients from Kuchaman

Culture reports reveal bacteria damaged cornea of five patients from Kuchaman

FSSAI prohibits Dabur from selling food products with ‘100%’ claims

FSSAI prohibits Dabur from selling food products with ‘100%’ claims

ORSL reinforces its commitment to improve diarrhoeal prevention in children

ORSL reinforces its commitment to improve diarrhoeal prevention in children

‘Donors got mixer grinders, cash’: blood banks in Bengal under scanner over ‘illegal’ sale to other States

‘Donors got mixer grinders, cash’: blood banks in Bengal under scanner over ‘illegal’ sale to other States

CREATE Medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license pact with Monash University

CREATE Medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license pact with Monash University